[{"Month":"August 2024","NewsReleases":[{"Title":"AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS","Date":"08.06.2024","Url":"/newsroom/press-releases/2024/08/amgen-reports-second-quarter-2024-financial-results"},{"Title":"AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND","Date":"08.02.2024","Url":"/newsroom/press-releases/2024/08/amgen-announces-2024-third-quarter-dividend"},{"Title":"AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS","Date":"08.01.2024","Url":"/newsroom/press-releases/2024/08/amgen-announces-webcast-of-2024-second-quarter-financial-results"}]},{"Month":"June 2024","NewsReleases":[{"Title":"FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE","Date":"06.14.2024","Url":"/newsroom/press-releases/2024/06/fda-approves-blincyto-blinatumomab-in-cd19positive-philadelphia-chromosomenegative-bcell-precursor-acute-lymphoblastic-leukemia-ball-in-the-consolidation-phase"},{"Title":"AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024","Date":"06.12.2024","Url":"/newsroom/press-releases/2024/06/amgen-to-present-innovative-rheumatology-research-at-eular-2024"}]}]